* Revance Therapeutics Inc is expected to show a rise in quarterly revenue when it reports results on May 9 for the period ending March 31 2024
* The Nashville Tennessee-based company is expected to report a 14.8% increase in revenue to $56.634 million from $49.33 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Revance Therapeutics Inc is for a loss of 75 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.
* Wall Street's median 12-month price target for Revance Therapeutics Inc is $12.00, above its last closing price of $3.95.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.76 -0.72 -0.62 Beat 14.4
Sep. 30 2023 -0.95 -0.85 -1.63 Missed -91.1
Jun. 30 2023 -0.79 -0.78 -0.80 Missed -2.9
Mar. 31 2023 -0.74 -0.70 -0.74 Missed -5.9
Dec. -1.05 -0.95 -0.95 Met -0.1
31 2022
Sep. 30 2022 -0.91 -0.89 -1.17 Missed -30.8
Jun. 30 2022 -0.89 -0.86 -0.88 Missed -2.3
Mar. 31 2022 -0.93 -0.83 -0.94 Missed -12.6
This summary was machine generated May 3 at 22:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments